rosetta inpharmatics Company Profile

16:31 EDT 22nd September 2017 | BioPortfolio

Rosetta Inpharmatics, a wholly owned subsidiary of Merck & Co. Inc., develops and implements technologies that will improve drug discovery. The company’s leading-edge genomic research and data analysis focus on how medical compounds affect biology, enabling more accurate selection of drug targets and more efficient drug development.

Rosetta Inpharmatics was founded in 1996 to design and implement DNA microarray gene expression technologies. The company was established with the goal to overcome the problems limiting the discovery and effective development of pharmaceutical and agricultural products. The founders include: Stephen Friend, M.D., Ph.D., the Company’s President and Chief Executive Officer; Leland Hartwell, Ph.D., and Leroy Hood, M.D., Ph.D. Rosetta Inpharmatics’ technology and patent portfolio were enhanced by its purchase of Acacia Biosciences, Inc. in February 1999, a company founded by Jasper Rine, Ph.D.

In October 1999, the Company signed a strategic partnership agreement with Agilent Technologies to further develop and commercialize Rosetta Inpharmatics’ FlexJet™ DNA microarrays . As part of this agreement, Agilent made a significant equity investment in Rosetta Inpharmatics.

In June 2000, Rosetta Inpharmatics successfully deployed its first commercially available bioinformatics system, the Rosetta Resolver® Gene Expression Data Analysis System. The Rosetta Resolver system was introduced to meet the demand for high-level gene expression analysis within the life sciences industries. It remains the flagship product of Rosetta Inpharmatics' business unit, Rosetta BioSoftware. Rosetta Inpharmatics became a publicly traded company on the Nasdaq National Market, under the stock symbol RSTA. The Company raised approximately $116 million from its initial public offering in August 2000.

In May 2001, Merck & Company announced it would acquire Rosetta Inpharmatics in a tax-free reorganization. The transaction had a net equity value of $620 million.


12040 115th Avenue NE
United States of America


Phone: 425-636-6377
Fax: 425-636-6398

News Articles [23 Associated News Articles listed on BioPortfolio]

Rosetta Genomics Ltd.: Rosetta Genomics Announces Pricing of $2.73 Million Financing

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / August 4, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and ac...

Rosetta Genomics Ltd.: Rosetta Genomics Announces Favorable Results from Two Pilot Studies Comparing RosettaGX Reveal and the Afirma GEC Assay for the Classification of Indeterminate Thyroid Nodules

Data Demonstrate Reveal Can Help Patients Avoid Substantially More Unnecessary Surgeries than the Current Market Leader PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / May 12, 2017 / Rosetta Ge...

Rosetta Genomics to divest PersonalizeDx for $2.9M

An all-cash agreement valued at $2.9 million was reached by Rosetta Genomics with health care business group Pragmin Prognosi -More- 

A touch of EroS

(Harvard Medical School) Researchers interested in the evolution of multicellular life were looking for bacteria that stimulate Salpingoeca rosetta, single-cell saltwater dwellers that are the closest...

Rosetta Genomics Ltd.: Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice

Laboratory's Entire Sales Team to Promote Reveal to All its Customers Throughout the Southwestern United States PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / August 21, 2017 / Rosetta Genomi...

Rosetta Genomics, Cytolog reach distribution deal for thyroid test

Cytolog Laboratories has agreed to exclusively distribute Rosetta Genomics' RosettaGX Reveal thyroid test in Brazil for undis -More- 

Rosetta Genomics eyes sale of PersonalizeDx business

Rosetta Genomics has announced plans for a potential sale of its PersonalizeDx business, which markets fluorescence in situ h -More- 

Securities offering could pull in $2.7M for Rosetta Genomics

A public offering of 1.9 million securities units has been priced by Rosetta Genomics in hopes of raising about $2.7 million. -More- 

Drugs and Medications [0 Results]


PubMed Articles [14 Associated PubMed Articles listed on BioPortfolio]

Network Inefficiency: A Rosetta Stone for the Mechanism of Anesthetic-induced Unconsciousness.

Modeling and docking of antibody structures with Rosetta.

We describe Rosetta-based computational protocols for predicting the 3D structure of an antibody from sequence (RosettaAntibody) and then docking the antibody to protein antigens (SnugDock). Antibody ...

LabRS: A Rosetta stone for retrospective standardization of clinical laboratory test results.

Clinical laboratories in the United States do not have an explicit result standard to report the 7 billion laboratory tests results they produce each year. The absence of standardized test results cre...

Electron and Ion Dynamics of the Solar Wind Interaction with a Weakly Outgassing Comet.

Using a 3D fully kinetic approach, we disentangle and explain the ion and electron dynamics of the solar wind interaction with a weakly outgassing comet. We show that, to first order, the dynamical in...

Using Triplet Ordering Preferences for Estimating Causal Effects in the Analysis of Gene Expression Data.

Triplet ordering preferences are used to perform Monte Carlo sampling of the posterior causal orderings originating from the analysis of gene-expression experiments involving observation as well as, u...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial

The ROSETTA-trial will evaluate the effect of acupuncture as a complementary treatment parallel to radiation therapy in oncological patients. The trial is designed as a two-armed trial. De...

Cognitive Brain Training in Older Adults

The investigators will conduct a 8-week proof-of-concept randomized controlled trial to provide preliminary evidence of efficacy of Fit Brains (Rosetta Stone Canada) training -- a mobile c...

Companies [10 Associated Companies listed on BioPortfolio]

rosetta inpharmatics

Rosetta Inpharmatics, a wholly owned subsidiary of Merck & Co. Inc., develops and implements technologies that will improve drug discovery. The company’s leading-edge genomic research and data analy...

Rosetta Genomics Ltd. and Biocept, Inc.

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state...

Rosetta Stone Inc.

Rosetta Stone Inc. is changing the way the world learns languages. Rosetta Stone provides interactive solutions that are acclaimed for the speed and power to unlock the natural la...

Rosetta Genomics

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and sta...

Rosetta Genomics, Ltd.

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the company’s integrative research platform combining bioinformatics and sta...

More Information about "rosetta inpharmatics" on BioPortfolio

We have published hundreds of rosetta inpharmatics news stories on BioPortfolio along with dozens of rosetta inpharmatics Clinical Trials and PubMed Articles about rosetta inpharmatics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of rosetta inpharmatics Companies in our database. You can also find out about relevant rosetta inpharmatics Drugs and Medications on this site too.

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record